Chimeric antigen receptor T-cell therapy has transformed the treatment of several blood cancers, yet its success often depends on how long engineered immune cells remain active after entering the body. A study published in Nature Cancer now identifies a metabolic threat that may help explain why these living drugs lose potency: iron-driven ferroptosis, a form of regulated cell death caused by the accumulation of damaging lipid peroxides. By integrating clinical data from patients with multiple myeloma and acute lymphoblastic leukemia, researchers found that CAR-T cells undergo a period of rapid expansion after infusion, followed by a distinct “diminution” phase marked by ferroptosis-associated molecular features and rising levels of iron in the bloodstream.
CAR-T therapy works by collecting a patient’s T cells, genetically modifying them to recognize a cancer-associated target, expanding them in the laboratory and returning them to the patient. Once infused, the cells can multiply dramatically and destroy malignant cells. That explosive expansion is widely regarded as a key indicator of therapeutic activity. However, the new findings suggest that the same period of intense proliferation may leave CAR-T cells metabolically vulnerable. As the population contracts, cells appear to encounter conditions in which excess iron, oxidative stress and altered lipid metabolism combine to undermine their survival and antitumor function.
The investigators reached this conclusion through integrated analyses of clinical samples obtained from people treated with CAR-T cells for multiple myeloma and acute lymphoblastic leukemia. Across these patient groups, the researchers observed changes consistent with ferroptosis during the post-expansion decline of the engineered T-cell population. Ferroptosis differs from apoptosis, the more familiar form of programmed cell death, because it is driven largely by iron-dependent oxidation of polyunsaturated fatty acids within cellular membranes. When lipid peroxides accumulate beyond the cell’s ability to neutralize them, membranes lose their integrity and the cell dies. The clinical observations linked this process with elevated serum iron, suggesting that iron availability may be more than a passive feature of treatment-related physiology.
To test whether iron directly damages CAR-T cells, the team used preclinical cancer models in female mice as well as ex vivo culture systems. Increasing the iron burden inside CAR-T cells impaired their ability to function effectively, while conditions that promoted ferroptosis weakened their antitumor activity. These experiments moved the study beyond correlation, indicating that iron can actively contribute to the loss of CAR-T performance. The results are particularly important because CAR-T cells must maintain several demanding functions at once: they must survive, proliferate, migrate toward malignant cells, form effective immune synapses and release cytotoxic molecules. Iron-associated stress appeared capable of disrupting this overall cellular program rather than affecting only one isolated response.
The researchers also traced part of the mechanism to mitochondria, the organelles that generate much of a cell’s energy. Excess intracellular iron can participate in chemical reactions that produce reactive oxygen species, highly reactive molecules capable of damaging proteins, DNA and lipids. In the CAR-T cells studied, iron increased mitochondrial reactive oxygen species and intensified lipid peroxidation. This creates a potentially destructive feedback loop: iron promotes oxidative reactions, damaged lipids compromise cellular membranes and organelles, and mitochondrial dysfunction generates still more oxidative stress. For activated T cells operating at high metabolic speed, that burden may be especially difficult to absorb.
A central component of the pathway was acyl-CoA synthetase long-chain family member 4, or ACSL4. This enzyme helps determine which fatty acids are incorporated into cellular membranes, including polyunsaturated fatty acids that are particularly susceptible to oxidation. By promoting the presence of oxidation-prone lipids, ACSL4 can make a cell more vulnerable to ferroptosis when iron and reactive oxygen species are abundant. The study’s findings connected ACSL4-associated lipid remodeling with the ferroptotic injury observed in CAR-T cells. In effect, the enzyme helps shape the molecular material that becomes damaged during iron-driven oxidative stress.
The most striking evidence came from experiments in which ACSL4 was genetically ablated in CAR-T cells. Removing the enzyme substantially improved the cells’ antitumor efficacy in preclinical models, supporting the idea that ferroptosis is not simply a marker of exhausted or dying cells but a targetable barrier to treatment durability. CAR-T cells lacking ACSL4 were better positioned to withstand the lipid damage associated with iron overload and retain their capacity to attack cancer. The results raise the possibility that engineering resistance to ferroptosis could become an additional design principle for next-generation cellular therapies, alongside improvements in antigen recognition, persistence and control of exhaustion.
The work also draws attention to the treatment environment surrounding CAR-T cells. Iron is essential for normal biology, including oxygen transport, DNA synthesis and mitochondrial metabolism, but its redox activity makes excess iron potentially hazardous. In patients receiving intensive cancer therapy, iron levels may be influenced by inflammation, transfusions, tissue damage, altered metabolism and the rapid destruction of malignant cells. The study does not establish that controlling serum iron alone would prevent CAR-T dysfunction, but it suggests that iron availability should be considered when researchers investigate why some engineered T-cell products persist while others decline. Monitoring iron-related signals could eventually help identify patients or treatment windows in which CAR-T cells are at greatest risk.
The findings point toward several possible therapeutic strategies, including pharmacological suppression of ferroptosis, metabolic interventions that limit lipid peroxidation and genetic engineering to remove or restrain ACSL4 activity. Any such approach would need to preserve the ability of CAR-T cells to expand and kill cancer while avoiding unwanted effects on other tissues. The study’s broader message is that the durability of cellular immunotherapy depends not only on immune recognition but also on the metabolic environment in which engineered cells operate. By identifying iron-driven ferroptosis as a mechanism of CAR-T cell dysfunction, the researchers provide a new explanation for post-infusion decline and a concrete molecular target for making these therapies more persistent and effective.
Subject of Research: Iron-driven ferroptosis and its effect on CAR-T cell persistence, function and antitumor efficacy.
Article Title: Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy
Article References: Kong, D., Yang, T., Zhao, M. et al. “Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.” Nature Cancer 7, 1243–1260 (2026). https://doi.org/10.1038/s43018-026-01187-2
Image Credits: AI Generated
DOI: 10.1038/s43018-026-01187-2
Keywords: CAR-T cells, ferroptosis, iron metabolism, ACSL4, lipid peroxidation, mitochondrial reactive oxygen species, cancer immunotherapy, multiple myeloma, acute lymphoblastic leukemia, cellular therapy
Tags: CAR-T Cell Therapychallenges in CAR T cell persistenceferroptosis in immune cellsferroptosis markers in blood cancersimpact of iron overload on immunotherapyiron metabolism and immune cell survivaliron-driven cell deathlipid peroxidation in cancer treatmentmechanisms of CAR-T cell exhaustionmetabolic vulnerabilities of CAR-T cellsoxidative stress in CAR-T cell functionregulation of T-cell lifespan post-infusion
